2008-07-28 23:54:03 -
www.researchandmarkets.com - Research and Markets (www.researchandmarkets.com/research/caedeb/indian_bulk_drugs) has announced the addition of the "Indian Bulk Drugs" report to their offering.
The Indian API (bulk drugs) manufacturing industry is estimated to have touched USD4.10 billion by 2007, growing at CAGR of 18.81% during 2003-07. India ranks fourth in terms of volume among the top 15 drug manufacturing countries. Cygnus releases the
latest version of the Indian Bulk Drugs Industry Insight to capture the present domestic market scenario, along with the major players and their key financials.
Key Findings & Highlights:
- The global pharmaceutical market was valued at USD712 billion in 2007.
- According to IMS Health, treatment costs per day declined by 20-40% in 2007 in therapy Areas
- Generics continued to replace branded prescriptions in the major therapeutic classes, increasing their share of total dispensed prescriptions to 67.3 %.
- In 2007, North America, which accounts for 45.9% of global pharmaceutical sales, grew by 4.2% to USD304.5 billion
- The market size for the global bulk drugs was USD77.32 billion in 2005 and was estimated to be USD92.21 billion in 2007
- Indian companies have the distinction of developing cost-effective technologies for manufacturing bulk drugs and intermediates that conform to global standards.
Reasons to Buy:
- Understand the global bulk drug market scenario
- Know investment opportunities according to the trend analysis
- Reveals the demand analysis of the bulk drugs industry
- Assess the cost effective technologies for manufacturing bulk drugs
Indian Bulk Drugs:
Given the significant export potential of the Indian bulk drugs industry, the latest version of the Indian Bulk Drugs Industry Insight has been released to capture the present domestic market scenario, along with the major players and their key financials. This report consists of 10 chapters. The overview of global bulk drugs market provides bulk drugs market size (2003-2007), segmental market size, the major players, and mergers and acquisition. It is followed by overview of Indian bulk drugs industry, which provides broad overview of the industry. The report then moves on to discuss the industry regulations, the growth drivers, and issues and challenges. The report comprises the profiles of 20 leading bulk drugs manufacturers with their SWOT analysis and outlook. The industry's critical success factors and future outlook are discussed to provide key inputs for understanding the industry.
Targeted Audience:
-Pharma Companies
-Bulk drug manufacturers
-Banks
-Students
Key Topics Covered:
- Global Bulk drugs Market - Market Overview
- Indian Bulk Drugs Market- an Overview
- Growth Drivers
- Industry Regulations
- Issues & Challenges
- Major Players
- Critical Success Factors
- Future Outlook
- List of Charts
- List of Tables
Companies Mentioned:
- Aurobindo Pharma
- Ranbaxy Laboratories
- Dr. Reddy's Laboratories
- Lupin Ltd
- Matrix Laboratories
- Cipla Ltd
- Orchid Chemicals and Pharmaceuticals Ltd
- Divis laboratories
- Sun Pharmaceutical Industries Ltd
- Ipca Laboratories Ltd
- Dishman Pharmaceutical and Chemicals Ltd
- Cadila Healthcare Ltd
- Alembic Ltd
- GlaxoSmithKline Pharmaceuticals Ltd
- Glenmark Pharmaceuticals Ltd
- Piramal Healthcare Limited (PHL)
- Unichem Laboratories Ltd
- Torrent Pharmaceuticals
- Merck India Ltd
- Atul Ltd
For more information visit
www.researchandmarkets.com/research/caedeb/indian_bulk_drugs
Research and Markets
Laura Wood, Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com 
